Europe posted its strongest venture funding quarter in four years, with $24 billion raised in Q2. The UK gained significant share, raising over $10 billion, and M&A activity picked up. AI-centric companies, including those spun out of Google DeepMind, drove large rounds.

Google researchers introduce HCC-STAR, a clinical-reasoning LLM for risk stratification and treatment guidance in hepatocellular carcinoma. This model achieves state-of-the-art performance in treatment recommendation and risk stratification. The study demonstrates the potential of AI in precision therapy for HCC patients.

Anthropic has unveiled Claude Science, a flagship AI product engineered to transform scientific research, particularly in computational biology and drug development. Positioned alongside Claude Code, this standalone offering empowers researchers to autonomously carry out complex tasks, marking a significant strategic leap for Anthropic into the life sciences domain and intensifying competition in AI for scientific discovery.